Algeta ASA : Algeta ASA : Further sub-analyses of ALSYMPCA phase III study presented at 2013 Genitourinary Cancers Symposium

  Algeta ASA : Algeta ASA : Further sub-analyses of ALSYMPCA phase III study
              presented at 2013 Genitourinary Cancers Symposium

Not Intended for US Media

Abstracts #11 & #19

     Effects of radium-223 dichloride on skeletal-related events and pain
  associated with bone metastases from castration-resistant prostate cancer

Oslo, Norway,  15 February  2013 -  Algeta ASA  (OSE: ALGETA)  announces  that 
further analyses  of  data  subsets  from the  phase  III  ALSYMPCA  study  of 
radium-223 dichloride  (radium-223)  in castration-resistant  prostate  cancer 
(CRPC)  patients  have  been  presented  at  the  2013  Genitourinary  Cancers 
Symposium^[1] (14-16 February 2013, Orlando, FL, USA).

Gillies O'Bryan-Tear, Algeta's Chief Medical Officer, said: "These  additional 
analyses from ALSYMPCA demonstrate that, in addition to prolonging survival in
CRPC patients  with  bone  metastases,  radium-223  also  improves  clinically 
relevant endpoints related to complications from bone metastases. If approved,
radium-223 has the potential to play a  key role in the treatment of men  with 
CRPC that has metastasized to the bone."

Abstract #11 by Vogelzang et al. found that radium-223 treatment significantly
delayed time to first skeletal-related event (SRE) versus placebo by a  median 
increase of 5.8  months (median  time to SRE:  15.6 vs  9.8 months;  HR=0.658; 
P<0.001). The analysis also showed that, compared to placebo in CRPC  patients 
with bone metastases, treatment  with radium-223 reduced the  risk of time  to 
first event for all four SRE components, including a 48% reduction in risk for
spinal cord compression.

Abstract #19 by  Nilsson et al.  described an analysis  of pain parameters  in 
ALSYMPCA. The analysis showed that, compared to placebo in CRPC patients  with 
bone metastases, patients treated with radium-223 had significantly  prolonged 
median time to first palliative  external beam radiotherapy (EBRT)  (HR=0.670, 
P=0.00117) and in  a post-hoc  analysis patients treated  with radium-223  had 
significantly prolonged  median  time  to  initial opioid  use,  with  a  risk 
reduction of 38% compared to placebo (HR=0.621).

In the ALSYMPCA trial the most common hematologic adverse events for  patients 
treated with  radium-223 and  best standard  of care  (BSoC) and  compared  to 
placebo and BSoC included  anemia (31% vs. 31%),  neutropenia (5% vs. 1%)  and 
thrombocytopenia (12% vs. 6%). With respect  to Grade 3 and 4 adverse  events, 
the most common events included anemia (13% vs. 13%), neutropenia (2% vs.  1%) 
and thrombocytopenia  (6% vs.  2%). The  most common  non-hematologic  adverse 
events in patients treated  with radium-223 and BSoC  compared to placebo  and 
BSoC included bone pain (50% vs. 62%), nausea (36% vs. 35%), diarrhea (25% vs.
15%) and vomiting (19% vs. 14%). With respect to Grade 3 to 4 adverse  events, 
the most common events included bone pain (21% vs. 26%).

References

Abstract #11 - Vogelzang, N. et al. Updated analysis of radium-223  dichloride 
(Ra-223)  impact   on  skeletal-related   events   (SRE)  in   patients   with 
castration-resistant prostate cancer (CRPC) and bone metastases from the phase
III randomized trial (ALSYMPCA).

Abstract #19 - Nilsson, S. et al. Pain analysis from the phase III  randomized 
ALSYMPCA study  with radium-223  dichloride (Ra-223)  in  castration-resistant 
prostate cancer (CRPC) patients with bone metastases.

                                     ###

About the ALSYMPCA Trial

The ALSYMPCA (ALpharadin  in SYMptomatic  Prostate CAncer) trial  was a  phase 
III,  randomized,  double-blind,  placebo-controlled  international  study  of 
radium-223 with  best  standard  of  care  (BSoC)  vs  placebo  with  BSoC  in 
symptomatic CRPC  patients  with  bone  metastases.  The  trial  enrolled  921 
patients in  more  than 100  centers  in  19 countries.  The  study  treatment 
consisted of up to  six intravenous administrations  of radium-223 or  placebo 
each separated by an interval of four weeks.

The primary endpoint of  the study was  overall survival. Secondary  endpoints 
included time to occurrence  of skeletal-related events  (SRE), time to  total 
alkaline phosphatase (ALP)  and prostate-specific  antigen (PSA)  progression, 
total ALP response and normalization, safety, and quality of life.

About CRPC and Bone Metastases

Prostate cancer is the most common non-cutaneous malignancy in men  worldwide. 
In 2008, an  estimated 899,000  men were  diagnosed with  prostate cancer  and 
258,000 died from the disease worldwide. Prostate cancer is the sixth  leading 
cause of death from cancer in men.

A majority of  men with CRPC  have radiological evidence  of bone  metastases. 
Once the cancer cells settle in  the bone, they interfere with bone  strength, 
often leading to pain, fracture and other complications that can significantly
impair a man's health. Bone metastases secondary to prostate cancer  typically 
target the lumbar spine,  vertebrae and pelvis. In  fact, bone metastases  are 
the main cause of morbidity and death in patients with CRPC.

About Radium-223 Dichloride

Radium-223 dichloride (radium-223), formerly referred  to as Alpharadin, is  a 
therapeutic alpha  particle-emitting pharmaceutical  with targeted  anti-tumor 
effect  on  bone  metastases  in  development  for  CRPC  patients  with  bone 
metastases.

In September 2009, Algeta  signed an agreement with  Bayer Pharma AG  (Berlin, 
Germany) for the  development and commercialization  of radium-223. Under  the 
terms of the agreement, Bayer will develop, apply for global health  authority 
approvals, and  commercialize  radium-223  globally.  Algeta  will  co-promote 
radium-223 with Bayer in  the US, and  is eligible for  milestones as well  as 
royalties on Bayer's sales outside the US. The ALSYMPCA trial was initiated by
Algeta in June 2008.

Radium-223 is an  investigational agent and  is not approved  by the  European 
Medicines Agency (EMA),  the US Food  and Drug Administration  (FDA) or  other 
health authorities. Bayer submitted  a Marketing Authorization Application  to 
the EMA and a New Drug Application to the FDA for radium-223 in December  2012 
for the treatment of CRPC patients with bone metastases, and received priority
review for the NDA in the US.

In terms of further  development activities for  radium-223, Bayer intends  to 
conduct studies in earlier settings of prostate cancer, including  combination 
studies with other agents, as well as exploratory studies in other tumors such
as breast cancer and osteosarcoma.

For further information, please contact:

Mike Booth                         +47 2202 4510
Communications & Corporate Affairs ir@algeta.com
Media enquiries:
Mark Swallow                       +44 207 638 9571
Citigate Dewe Rogerson             mark.swallow@citigatedr.co.uk
Knut Ekern                         +47 22 04 82 00
Gambit Hill & Knowlton             knut.ekern@hkstrategies.com
US investor enquiries:
Tricia Swanson                     +1 646 378 2953
The Trout Group                    tswanson@troutgroup.com

About Algeta

Algeta is  a  company  focused  on developing  novel  targeted  therapies  for 
patients with cancer based on  its alpha-pharmaceutical platform. The  Company 
is headquartered in  Oslo, Norway, and  has a US  subsidiary, Algeta US,  LLC, 
based in Cambridge, MA performing  commercial marketing operations in the  US. 
Algeta is  listed  on the  Oslo  Stock  Exchange (Ticker:  ALGETA).  For  more 
information please visit www.algeta.com.

Forward-looking Statements



This news release contains certain  forward-looking statements that are  based 
on uncertainty, as they relate to events and depend on circumstances that will
occur in the future and which, by their nature, may have an impact on  results 
of operations  and the  financial condition  of Algeta.  Such  forward-looking 
statements reflect  our  current  views  and  are  based  on  the  information 
currently available to Algeta. Algeta cannot give any assurance as to  whether 
such forward  looking  statements will  prove  to be  correct.  These  forward 
looking statements include statements  regarding our anticipated  co-promotion 
of radium-223 in  the US.  There are  a number  of factors  that could  cause 
actual results and developments to  differ materially from those expressed  or 
implied by  these forward-looking  statements.  These factors  include,  among 
other things, risks or uncertainties  associated with the ability to  identify 
and hire a sufficient  number of qualified employees  for the US field  force, 
growth management, general  economic and business  conditions and the  pricing 
environment,  the  impact   of  competition,  the   ability  to   successfully 
commercialize radium-223, the risk that costs associated with the co-promotion
of radium-223 may  be greater  than anticipated,  manufacturing capacity,  the 
risk of non-approval of patents not yet granted, risks in obtaining regulatory
approvals for radium-223 and  the other risks  and uncertainties described  in 
our annual report.

[1]The 2013 Genitourinary Cancers Symposium is co-sponsored by the American
Society of Clinical Oncology (ASCO), the American Society for Radiation
Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Algeta ASA via Thomson Reuters ONE
HUG#1678363
 
Press spacebar to pause and continue. Press esc to stop.